Hepatitis B virus surface protein-induced hPIAS1 transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways
暂无分享,去创建一个
Xiaofeng Wang | Q. Ning | Xiaoping Luo | Weiming Yan | Meifang Han | Guang Chen | Di Wu | Hongyang Wang | Yuanya Zhang
[1] D. Murray,et al. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. , 2016, Leukemia research.
[2] Y. Shyr,et al. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias. , 2015, Leukemia research.
[3] Pinar Ozkal-Baydin. How did hepatitis B virus effect the host genome in the last decade? , 2014, World journal of hepatology.
[4] H. Mollenkopf,et al. Pathological Impact of Hepatitis B Virus Surface Proteins on the Liver Is Associated with the Host Genetic Background , 2014, PloS one.
[5] Jun Zhang,et al. PIAS1 negatively modulates virus triggered type I IFN signaling by blocking the DNA binding activity of IRF3. , 2013, Antiviral research.
[6] Y. Liaw,et al. Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels , 2013, Hepatology.
[7] J. Chen,et al. [Hepatitis B surface antigen affects the expression of lipid metabolism-related genes in HepG2 cells]. , 2013, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
[8] M. Heikenwalder,et al. Direct Effects of Hepatitis B Virus-Encoded Proteins and Chronic Infection in Liver Cancer Development , 2013, Digestive Diseases.
[9] Y. L. Ma,et al. NMDA receptor signaling mediates the expression of protein inhibitor of activated STAT1 (PIAS1) in rat hippocampus , 2013, Neuropharmacology.
[10] J. V. van Dissel,et al. Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-β. , 2013, Cytokine.
[11] H. Salem,et al. The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[12] Subrata Ghosh. A Journey with the Journal , 2013 .
[13] G. Raimondo,et al. Hepatocellular carcinoma: the point of view of the hepatitis B virus. , 2011, Carcinogenesis.
[14] C. Boucher,et al. Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.
[15] Kook Hwan Kim,et al. Hepatitis B Virus X Protein Impairs Hepatic Insulin Signaling Through Degradation of IRS1 and Induction of SOCS3 , 2010, PloS one.
[16] W. Liu,et al. Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. , 2010, Antiviral research.
[17] Zhan-qing Zhang,et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. , 2009, Molecular immunology.
[18] T. Asselah,et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.
[19] Wei Guo,et al. Hepatitis B Virus-induced hFGL2 Transcription Is Dependent on c-Ets-2 and MAPK Signal Pathway* , 2008, Journal of Biological Chemistry.
[20] V. Chongsuvivatwong,et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. , 2008, World journal of gastroenterology.
[21] E. Baixeras,et al. Liver expression of proteins controlling interferon‐mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection , 2007, The Journal of pathology.
[22] V. Deleuze,et al. TAL-1/SCL and Its Partners E47 and LMO2 Up-Regulate VE-Cadherin Expression in Endothelial Cells , 2007, Molecular and Cellular Biology.
[23] Y. Chawla,et al. Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator on Treatment of Chronic Hepatitis B , 2007, The American Journal of Gastroenterology.
[24] M. Nassal,et al. Inhibition of Alpha Interferon Signaling by Hepatitis B Virus , 2006, Journal of Virology.
[25] M. Campbell. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BLau GKK, for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (Univ of Hong Kong, China; et al) N Engl J Med 352:2682–2695, 2005§ , 2006 .
[26] Thomas Berg,et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.
[27] Hong Wu,et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity , 2004, Nature Immunology.
[28] M. Rudnicki,et al. Cellular and molecular regulation of muscle regeneration. , 2004, Physiological reviews.
[29] N. La Monica,et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. , 2004, Gastroenterology.
[30] T. Hoang,et al. SCL: from the origin of hematopoiesis to stem cells and leukemia. , 2004, Experimental hematology.
[31] Man-Fung Yuen,et al. Viral hepatitis B , 2003, The Lancet.
[32] P. Duerksen-Hughes,et al. Protein kinases and their involvement in the cellular responses to genotoxic stress. , 2003, Mutation research.
[33] R. Gronostajski,et al. Roles of the NFI/CTF gene family in transcription and development. , 2000, Gene.
[34] C. Bréchot,et al. Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. , 1999, The Journal of general virology.
[35] D. Chang,et al. Inhibition of Stat1-mediated gene activation by PIAS1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] C. Peschle,et al. Chromatin immunoselection defines a TAL‐1 target gene , 1998, The EMBO journal.
[37] M. Chen,et al. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. , 1998, Journal of immunology.
[38] P Jay,et al. Specific inhibition of Stat3 signal transduction by PIAS3. , 1997, Science.
[39] F. Zoulim,et al. Heterogeneity of hepatitis B virus (HBV) core gene in a patient with HBV-associated cirrhosis and serum negativity for anti-HBc. , 1996, Journal of hepatology.
[40] G. Fattovich,et al. Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis , 1996 .
[41] R. Kingston,et al. Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins , 1994, Molecular and cellular biology.
[42] S. Iino. [Interferon therapy of chronic hepatitis]. , 1992, Nihon rinsho. Japanese journal of clinical medicine.
[43] T. Tokino,et al. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. , 1990, Molecular biology & medicine.
[44] Robert Tjian,et al. A cellular DNA-binding protein that activates eukaryotic transcription and DNA replication , 1987, Cell.
[45] J. Hurwitz,et al. Adenovirus DNA replication in vitro: identification of a host factor that stimulates synthesis of the preterminal protein-dCMP complex. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[46] H. Saito. Interferon therapy in chronic hepatitis B. , 1976, Lancet.